Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08:00 | Verici Dx PLC - Final Results | - | RNS | ||
11.06. | Verici Dx plant Kapitalerhöhung zur Unterstützung des Tutivia-Test-Wachstums | 3 | Investing.com Deutsch | ||
VERICI DX Aktie jetzt für 0€ handeln | |||||
11.06. | Verici Dx PLC - Update on funding to accelerate commercial growth | - | RNS | ||
27.05. | Verici Dx shareholders approve resolutions at general meeting | 1 | Investing.com | ||
27.05. | Verici Dx PLC - Result of General Meeting | 1 | RNS | ||
09.05. | Verici Dx plant Aktionärsversammlung zur Genehmigung neuer Aktienemission | - | Investing.com Deutsch | ||
09.05. | Verici Dx plans shareholder meeting to approve new share issue | 1 | Investing.com | ||
09.05. | Verici Dx PLC - Publication of Circular | 2 | RNS | ||
10.04. | AIM Market Roundup: Ethernity Networks, Verici DX, Aferian | 2 | The Armchair Trader | ||
10.04. | Medicare approves Verici Dx's Tutivia for coverage | 2 | Investing.com | ||
10.04. | Medicare genehmigt Kostenübernahme für Tutivia von Verici Dx | 1 | Investing.com Deutsch | ||
10.04. | Verici Dx PLC - Verici Receives Medicare Coverage for Tutivia | - | RNS | ||
07.04. | Verici Dx shares dive 58% as cuts outlook despite more Tutivia orders | - | Alliance News | ||
07.04. | Verici Dx reports record Tutivia orders, downgrades revenue outlook | 2 | Sharecast | ||
07.04. | Verici Dx PLC - Significant Test Growth with Medicare Pending | - | RNS |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | 0,00 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | 0,00 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | 0,00 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | 0,00 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | 0,00 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | 0,00 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
QIAGEN | 41,175 | +0,43 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | ||
EVOTEC | 7,228 | +1,26 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
NUVALENT | 79,66 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen |